



**Office of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda***

December 9, 2008 6:30 – 9:00 p.m. **

- 1. Executive Session** **6:30 - 7:00**
 - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))
- 2. Introductions and Approval of DUR Board Minutes** **7:00 - 7:05**

(Public Comment Prior to Board Action)
- 3. OVHA Pharmacy Administration Updates** **7:05 - 7:15**
- 4. Medical Director Update** **7:15 - 7:25**
 - Clinical Programs Update
 - Prescriber Comments
- 5. Follow-up Items from Previous Meeting** **7:25 - 7:25**
 - No items
- 6. Clinical Update: Drug Reviews** **7:25 – 7:35**

(Public comment prior to Board action)

 - Relestor[®] (methylnaltrexone) injection
- 7. Review of Newly-Developed/Revised Clinical Coverage Criteria** **7:35 – 8:30**

(Public comment prior to Board action)

 - Acne Drugs: Topical Anti-Infectives
 - Anti-hypertensives: ARB Combinations (Azor[®])
 - Anti-hypertensives: Renin Inhibitors (Tekturna[®]/Tekturna HCT[®])
 - Anti-Infectives: Cephalosporins (Suprax[®] tablet)
 - Anti-psychotics: Atypicals and Combinations (Seroquel XR[®])
 - Mood Stabilizers (Equetro[®])
 - Ophthalmic Antihistamines
 - Ossification Enhancing Agents (Fortical[®])
 - Pulmonary: Beta-Agonists: Short Acting Metered Dose Inhalers (Maxair[®] brief review)
 - Pulmonary: Inhaled Glucocorticoids: Single Agent Metered Dose Inhaler (QVAR[®] brief review)
- 8. Drug Classes – Annual Review** **8:30 – 8:35**

(Public comment prior to Board action)

Anti-Diabetics

 - Insulin
 - Oral

- Alpha Glucosidase Inhibitors
- Biguanides and Combinations
- Meglitinides
- Sulfonylureas (Second Generation)
- Thiazolidinediones and Combinations
- Dipeptidyl Peptidase Inhibitors and Combinations
- Peptide Hormones

9. RetroDUR	8:35 - 8:45
▪ Chantix® and Smoking Cessation Products	
10. New Drug Product Plan Exclusions (Consent Agenda Topic)	8:45 - 8:50
11. Updated New-to-Market Drug Monitoring Log	8:50 - 8:55
12. General Announcements	8:55 - 9:00
Selected FDA Safety Alerts	
▪ Bisphosphonates - atrial fibrillation	
13. Adjourn	9:00